Top Markets
Coin of the day
Venus Medtech (Hangzhou) Inc. Venus Medtech (Hangzhou) Inc.

Venus Medtech (Hangzhou) Inc.

2500
株式のランク #24714
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the... Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
株価
$0.13048475
時価総額
$57.55M
変化(1日)
-1.92%
変化(1年)
-77.88%
CN
取引 Venus Medtech (Hangzhou) Inc. (2500)

カテゴリー

Venus Medtech (Hangzhou) Inc.(2500)の利益
2026 時点の利益 TTM: 0
Venus Medtech (Hangzhou) Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Venus Medtech (Hangzhou) Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。